Hubei Biocause Pharmaceutical (000627) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hubei Biocause Pharmaceutical (000627) has a cash flow conversion efficiency ratio of 0.008x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥276.06 Million ≈ $40.40 Million USD) by net assets (CN¥33.70 Billion ≈ $4.93 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Hubei Biocause Pharmaceutical (000627) balance sheet quality index to measure how much of total assets are equity-financed.
Hubei Biocause Pharmaceutical - Cash Flow Conversion Efficiency Trend (2001–2023)
This chart illustrates how Hubei Biocause Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Hubei Biocause Pharmaceutical cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Hubei Biocause Pharmaceutical Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hubei Biocause Pharmaceutical ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Topsec Technologies Group Inc
SHE:002212
|
-0.018x |
|
Shanghai Yaoji Playing Card Co Ltd
SHE:002605
|
0.044x |
|
AS LHV GROUP EO -10
F:ASU0
|
N/A |
|
Zhe Jiang Dali Technology Co Ltd
SHE:002214
|
0.049x |
|
Jiuzhitang Co Ltd
SHE:000989
|
0.026x |
|
Suzhou Huaya Intelligence Technology Co Ltd
SHE:003043
|
0.014x |
|
UOA Development Bhd
KLSE:5200
|
0.005x |
|
Jingjin Environmental Protection Co Ltd
SHG:603279
|
0.050x |
Annual Cash Flow Conversion Efficiency for Hubei Biocause Pharmaceutical (2001–2023)
The table below shows the annual cash flow conversion efficiency of Hubei Biocause Pharmaceutical from 2001 to 2023. For the full company profile with market capitalisation and key ratios, see Hubei Biocause Pharmaceutical market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | CN¥33.63 Billion ≈ $4.92 Billion |
CN¥9.53 Billion ≈ $1.40 Billion |
0.283x | +30.37% |
| 2022-12-31 | CN¥34.60 Billion ≈ $5.06 Billion |
CN¥7.52 Billion ≈ $1.10 Billion |
0.217x | +95.29% |
| 2021-12-31 | CN¥37.47 Billion ≈ $5.48 Billion |
CN¥4.17 Billion ≈ $610.58 Million |
0.111x | -82.02% |
| 2020-12-31 | CN¥34.59 Billion ≈ $5.06 Billion |
CN¥21.42 Billion ≈ $3.13 Billion |
0.619x | -25.61% |
| 2019-12-31 | CN¥34.35 Billion ≈ $5.03 Billion |
CN¥28.60 Billion ≈ $4.19 Billion |
0.833x | +44.56% |
| 2018-12-31 | CN¥26.01 Billion ≈ $3.81 Billion |
CN¥14.98 Billion ≈ $2.19 Billion |
0.576x | +3463.41% |
| 2017-12-31 | CN¥26.70 Billion ≈ $3.91 Billion |
CN¥431.58 Million ≈ $63.15 Million |
0.016x | +114.07% |
| 2016-12-31 | CN¥20.40 Billion ≈ $2.98 Billion |
CN¥-2.34 Billion ≈ $-342.76 Million |
-0.115x | -338.31% |
| 2015-12-31 | CN¥1.78 Billion ≈ $261.01 Million |
CN¥-46.73 Million ≈ $-6.84 Million |
-0.026x | -128.83% |
| 2013-12-31 | CN¥1.44 Billion ≈ $210.17 Million |
CN¥130.53 Million ≈ $19.10 Million |
0.091x | +48.97% |
| 2012-12-31 | CN¥1.54 Billion ≈ $224.96 Million |
CN¥93.79 Million ≈ $13.72 Million |
0.061x | +28.87% |
| 2011-12-31 | CN¥1.41 Billion ≈ $206.93 Million |
CN¥66.95 Million ≈ $9.80 Million |
0.047x | -66.23% |
| 2010-12-31 | CN¥1.60 Billion ≈ $234.43 Million |
CN¥224.58 Million ≈ $32.86 Million |
0.140x | +2.40% |
| 2007-12-31 | CN¥866.03 Million ≈ $126.73 Million |
CN¥118.56 Million ≈ $17.35 Million |
0.137x | -22.71% |
| 2006-12-31 | CN¥723.71 Million ≈ $105.90 Million |
CN¥128.19 Million ≈ $18.76 Million |
0.177x | +166.20% |
| 2005-12-31 | CN¥731.23 Million ≈ $107.00 Million |
CN¥48.66 Million ≈ $7.12 Million |
0.067x | -14.08% |
| 2004-12-31 | CN¥723.91 Million ≈ $105.93 Million |
CN¥56.07 Million ≈ $8.20 Million |
0.077x | +58.41% |
| 2001-12-31 | CN¥762.99 Million ≈ $111.65 Million |
CN¥37.30 Million ≈ $5.46 Million |
0.049x | -- |
About Hubei Biocause Pharmaceutical
Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. It also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, the company is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ethe… Read more